Philippe Moreau, MD, serves as Professor of Clinical Hematology at the University Hospital of Nantes, France. Professor Moreau's clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.

Professor Moreau is president of International Myeloma Society (IMS) since 2023, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator of several international clinical trials evaluating Bortezomib, Carfizomib, Ixazomib, Pomalidomide, Venetoclax, Daratumumab, Isatuximab, or Teclistamab. He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris, and was the chairman of the French cooperative group IFM from 2006 to 2009 and from 2020 to 2023.

His research is widely published, with more than 500 peer-reviewed articles and reviews that have appeared in high impact factor journals including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, and Blood. He is frequently invited speaker at international hematologic oncology meetings, and during Educational Session on Multiple Myeloma at ASH, ASCO or EHA.

Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.